What is UZEDY?
UZEDY (risperidone) is an extended-release injectable formulation of risperidone, classified as an atypical antipsychotic. It treats adults with schizophrenia by blocking dopamine D2 and serotonin 5-HT2A receptors in the brain, helping control symptoms like hallucinations and delusions.
How is UZEDY administered?
UZEDY comes as a subcutaneous injection given monthly (50 mg or 100 mg) or every two months (150 mg or 200 mg). It's designed for long-acting delivery using a proprietary phospholipid-based technology, reducing the need for daily pills.[1]
How does UZEDY differ from oral risperidone?
Oral risperidone requires daily dosing and has variable absorption. UZEDY provides steady release over 1-2 months, improving adherence for patients who struggle with pills. Both share the same active ingredient and mechanism but UZEDY avoids first-pass metabolism for more consistent blood levels.[1][2]
Who makes UZEDY and when was it approved?
Teva Pharmaceuticals and MedinCell developed UZEDY. The FDA approved it in April 2023 for schizophrenia maintenance after a 52-week trial showed non-inferiority to daily oral risperidone.[1]
What are common side effects?
Patients report injection-site reactions (pain, swelling), weight gain, drowsiness, and movement disorders like akathisia. Long-term risks include elevated prolactin, metabolic changes, and tardive dyskinesia. Monitoring is required.[1][2]
When does UZEDY's patent protection end?
Core patents for UZEDY's formulation (e.g., US Patent 10,792,234 on the delivery tech) expire around 2037-2040. No generic challenges listed yet on DrugPatentWatch.com.[3]
How does UZEDY compare to other long-acting antipsychotics?
| Drug | Active Ingredient | Dosing Interval | Key Difference |
|------|-------------------|-----------------|---------------|
| UZEDY | Risperidone | 1-2 months (subQ) | Steady release, no loading dose |
| Risperdal Consta | Risperidone | 2 weeks (IM) | Requires oral supplementation initially |
| Invega Sustenna | Paliperidone | 1 month (IM) | Metabolite of risperidone; higher cost |
| Abilify Maintena | Aripiprazole | 1 month (IM) | Partial D2 agonist; fewer metabolic effects |
UZEDY stands out for subcutaneous ease over intramuscular injections.[1][2]
Sources:
[1] UZEDY Prescribing Information
[2] FDA Approval Label
[3] DrugPatentWatch.com - UZEDY Patents